Tanox and Sunol Molecular entered into licensing agreement to acquire rights to Sunol’s tissue factor antagonist for treating inflammatory disease and cancer including tissue factor antagonist cH36, a chimeric antitissue factor monoclonal antibody for treating acute lung injury and acute respiratory distress syndrome.